Nektar Therapeutics
NASDAQ:NKTR
Gross Margin
Nektar Therapeutics
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | US |
| Market Cap | 325m USD |
| Gross Margin |
61%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Gross Margin |
-3%
|
| Country | US |
| Market Cap | 744.4B USD |
| Gross Margin |
80%
|
| Country | DK |
| Market Cap | 4.1T DKK |
| Gross Margin |
85%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Gross Margin |
56%
|
| Country | US |
| Market Cap | 367.4B USD |
| Gross Margin |
70%
|
| Country | US |
| Market Cap | 333.6B USD |
| Gross Margin |
75%
|
| Country | UK |
| Market Cap | 188.7B GBP |
| Gross Margin |
82%
|
| Country | CH |
| Market Cap | 182.5B CHF |
| Gross Margin |
74%
|
| Country | CH |
| Market Cap | 181.4B CHF |
| Gross Margin |
73%
|
| Country | US |
| Market Cap | 162.7B USD |
| Gross Margin |
70%
|
Profitability Report
View the profitability report to see the full profitability analysis for Nektar Therapeutics.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Nektar Therapeutics's most recent financial statements, the company has Gross Margin of 60.9%.
You don't have any saved screeners yet
